Can Mounjaro Affect Your Heart? What the Evidence Shows

Step 1 (Understand what happens to your heart when you start tirzepatide

When you inject your first pen and keep it in the fridge door ready for the following week, the medicine begins working on two receptors) GIP and GLP-1, that regulate appetite, gastric emptying, and blood-sugar handling. One downstream effect of GLP-1 receptor activation is a small increase in resting heart rate. Clinical trial data across the SURMOUNT programme showed an average rise of around two to three beats per minute at therapeutic doses, which is generally considered mild and clinically unremarkable for most adults. For people who already have a fast resting pulse or certain rhythm disorders, it is worth flagging to the prescriber, and you can find a thorough explanation of how Mounjaro can affect your heart in our dedicated clinical overview.

Blood pressure typically moves in the other direction. As body weight falls, systolic and diastolic blood pressure tend to fall with it, an effect seen consistently in trial participants taking tirzepatide. For people who are taking antihypertensive medicines, this is something a prescriber monitors, because dose adjustments to those medicines may eventually become relevant.

The NHS medicines page for tirzepatide lists palpitations among the less common reported side effects. If your heart feels like it is beating harder or faster than normal in the days after a dose increase, that is worth noting and reporting to your clinical team.

Step 2, Weigh up what the trial evidence does (and does not) tell us

The SURMOUNT-1 trial, which enrolled 2,539 adults with obesity, reported no increase in major adverse cardiovascular events compared with placebo over 72 weeks. That is reassuring, though the study was not specifically designed to test cardiovascular outcomes the way a dedicated cardiac trial would be.

The picture is different for semaglutide. Wegovy holds a specific UK authorisation for reducing major cardiovascular event risk in eligible adults, an indication built on the SELECT trial. Tirzepatide does not yet hold that separate indication in the UK. A dedicated cardiovascular outcomes trial for tirzepatide is underway; results are awaited. Until those data are published, the honest answer is that tirzepatide's cardiovascular effect profile looks broadly positive on indirect measures, but the definitive outcome evidence is still being gathered. Prescribers and patients should understand that distinction. If cardiovascular risk reduction is a specific clinical priority for you, discuss which medicine best fits that goal with your clinician, you can read more about the broader Mounjaro evidence base on the tirzepatide treatment overview.

NICE's appraisal of tirzepatide (TA1026) acknowledges cardiovascular disease as one of the qualifying weight-related comorbidities for NHS eligibility, which reflects the clinical importance of reducing cardiovascular risk through sustained weight loss, even before a formal cardiovascular outcome trial concludes.

Step 3, Know the signs that need prompt medical attention

Most people on tirzepatide have no cardiac symptoms at all. For those who do notice something, the distinction between a benign transient effect and one that needs medical review matters.

Contact a clinician promptly if you experience chest pain, an irregular heartbeat that persists, shortness of breath on minimal exertion, or a resting heart rate that is consistently much higher than your baseline. These symptoms are not characteristic of tirzepatide's known pharmacology and could indicate something unrelated that needs assessment.

Palpitations that start immediately after a dose and fade within a day or two are more likely to be a direct GLP-1 effect. They are still worth mentioning to your prescriber, who may decide to extend the titration period rather than increase the dose on the standard schedule.

People with a history of arrhythmia, congestive heart failure, recent myocardial infarction, or coronary artery disease are not automatically excluded from tirzepatide, but the benefit-risk discussion is more detailed. Cardiology input alongside prescribing is appropriate in those cases. Questions about how Mounjaro may interact with other organs come up regularly, our clinical team at nume's prescribing team page gives a sense of who reviews those decisions. For the liver angle, there is a separate piece on how tirzepatide interacts with liver function, which some people find useful alongside this one.

Step 4, What this means in practice before you start

A good consultation captures your cardiac history, current medications (including antihypertensives and anti-arrhythmics), and resting heart rate as a baseline. That is exactly what the process at a regulated UK pharmacy should do, and what ours does. The prescriber's job is not just to confirm BMI eligibility but to map the medicine against your specific physiology.

If you are curious about how heart rate specifically changes during treatment, there is a detailed look at that on the page covering Mounjaro and heart rate changes. For thyroid-related questions that sometimes come up alongside cardiac queries, the tirzepatide and thyroid page covers the current evidence there too.

Cost is a practical factor for many people considering private treatment. The context around Eli Lilly's UK price changes explains how the market has shifted since 2025. Once you are ready to have your own clinical picture properly assessed, speaking to our prescribers is the natural next step, no waiting list, reviewed the same day.